ClinicalTrialsFinder
RecruitingNot ApplicableNCT06884163

Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics

Characterization of the Immune Signature of Chronic Hand Eczema With an Innovative Approach Combining Spatial Transcriptomics and Single Cell Spatial Proteomics

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

40 participants

Start Date

Jan 13, 2025

Study Type

INTERVENTIONAL

Conditions

Hand Eczema

Summary

The study explores the immune landscape of chronic hand eczema using spatial transcriptomics and single-cell proteomics, offering new insights into disease mechanisms and potential therapeutic targets.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • Patients affected with chronic hand eczema of endogenous and/or exogenous origin, age from 18 to 65 years
  • Patients affected with eczema located on the hands for at least 3 months or with ≥ 2 disease flare-ups in the last year.
  • Patients affected with atopic dermatitis affecting the hands and other areas of the body, provided the eczema lesions involve less than 30% of the body surface area.

Exclusion Criteria4

  • Concurrent or previous treatment with immunosuppressants, except for short courses of systemic corticosteroids (less than one month of continuous treatment), or biologic agents that may affect the clinical aspects or progression of chronic hand eczema.
  • Patients who have received systemic corticosteroids within one month prior to enrollment in the study.
  • Patients using topical corticosteroids or calcineurin inhibitors within one week of study enrollment (this time frame is considered to provide a good balance between potential residual pharmacological effects and ethical considerations).
  • Patients with chronic hand eczema of mixed etiology (e.g., allergic and atopic) or those considered "etiologically unclassifiable" will not be included in the data analysis.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICcomprhensive spatial transcriptomic profile on lesional skin biopsies

Spatial transcriptomics (Visium, 10X Genomics) will be used to analyze gene expression of chronic eczema derived from lesional skin biopsies

Locations(1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06884163